In this interview with Targeted Oncology managing editor Sabrina Serani, Estelamari Rodriguez, MD, MPH, hematologist-oncologist at Sylvester Comprehensive Cancer Center, discusses ...

SER-155 is an oral live biotherapeutic being investigated to treat disruptive conditions of the gastrointestinal tract. In a ...

The first clinical case presents a 58-year-old female never-smoker with persistent cough, mild dyspnea, and new right-sided ...

The panel discusses the full multidisciplinary team required to optimize outcomes for patients with ROS1-positive advanced ...

FDA clears perioperative pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, boosting event-free and overall survival ahead of cystectomy. The FDA has approved pembrolizumab ...

A phase 3 randomized study found no OS benefit from adding 30 Gy/10 fractions thoracic radiotherapy starting after cycle 1 to ...

In this episode of The Moonlight Shift, Gina Mauro sits down with two rising stars in hematology-oncology at the same terrifying threshold: the end of fellowship and the beginning ...

Subcutaneous isatuximab is now approved with pomalidomide/dexamethasone, carfilzomib/dexamethasone, and bortezomib/lenalidomide/dexamethasone, aligning SC ...

The second clinical case presents a patient with ROS1 fusion-positive advanced NSCLC who achieved partial response on ...

Pettit, MD, and participants discussed second-line considerations in high-risk polycythemia after hydroxyurea failure.

FDA NDA acceptance for varegacestat positions it as a potential second oral targeted option for progressing desmoid tumors, ...

Bispecific antibodies have emerged as a transformative class of therapies in multiple myeloma and beyond, but the need for ...